USTR Opens Section 301 Investigation into Germany’s Pharmaceutical Pricing
USTR has launched a Section 301 investigation into Germany's pharmaceutical pricing and reimbursement practices. The probe will assess whether Germany's policies unfairly burden U.S. commerce by shifting a disproportionate share of global pharmaceutical research and development costs to American patients and manufacturers.